VREOF Vireo Growth Inc.
Vireo Growth (VREOF) news
Vireo Growth Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker VREOF, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Vireo Growth news
We have not published a story on Vireo Growth yet. When there is news, it will appear here.
Vireo Growth annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $268.8 million | $99.4 million |
| Net income (loss) | -$68.1 million | -$28.0 million |
| Cash from operations | $3.7 million | -$10.2 million |
| Cash and equivalents | $122.5 million | $91.6 million |
| Short-term investments | $1.0 million |
Questions about Vireo Growth
What is the ticker symbol of Vireo Growth?
Vireo Growth Inc. trades under the ticker VREOF on OTC.
Where is Vireo Growth listed?
Vireo Growth Inc. is listed on OTC.
Which country or territory is Vireo Growth listed under?
Our directory records Vireo Growth Inc. under United States.
Does aibio.space cover Vireo Growth?
aibio.space lists Vireo Growth Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What was Vireo Growth's revenue last year?
$268.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Vireo Growth profitable?
Vireo Growth Inc. reported a net loss of $68.1 million for the fiscal year ended Dec 31, 2025, and generated $3.7 million of cash from operations, per its annual report to the SEC.
How much cash does Vireo Growth have?
$123.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Investor discussion: Vireo Growth
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,7.01,9.01). Source
- Financings
Announced a share repurchase program. SEC Form 8-K (Items 7.01,8.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 425. Source
- Distress
Reported a bankruptcy filing. SEC Form 8-K (Items 1.01,7.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,7.01,9.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 7.01,8.01,9.01). Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,7.01,9.01). Source
Stock chart
Listing details
- Company
- Vireo Growth Inc.
- Ticker
- VREOF
- Listing
- OTC
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio